Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSPREY: JNJ-73763989 + JNJ-64300535 in Chronic Hepatitis B
NCT05123599Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Prophylactic Vaccines, Conjugated siRNA, DNA Vaccines
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of tomligisiran and JNJ-64300535 in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with a Reduction of at Least 2 log10 International Units per Milliliter (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels at Week 36. Started Dec 2021; status: completed.
02
Drugs
tomligisiranJNJ-64300535
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05123599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123599.